At Interpace Diagnostics, we leverage the latest technology to develop and commercialize novel molecular diagnostic tests to detect genetic alterations that are associated with gastrointestinal, endocrine and lung cancer existence or risk, which are principally focused on early detection and identification of high potential progression to cancer.
|Indication||Thyroid Cancer||Thyroid Cancer||Pancreatic & Biliary Cancer||Lung Cancer||Esophageal Cancer|
|Diagnostic Test||NGS Panel for Thyroid Cancer||MicroRNA Risk Classifier for Thyroid Cancer||Risk-Stratifies, Pancreatic Cysts, Pancreaticobiliary Solid Lesions||Risk of New Primary Cancer Formation vs. Metastases or Recurrence||Risk-Stratifies for Esophageal Cancer|
|Diagnostic Report||Rules In Thyroid Cancer||Rules Out Thyroid Cancer||Rules In and Rules Out Pancreatic or Biliary Cancer||Rules In and Rules Out New Primary Cancer Formation||Rules In Higher Risk of Progression of Esophageal Cancer|
PancraGEN® is a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess the risk of pancreaticobiliary cancers using our proprietary PathFinderTG® platform. Also known as "Integrated Molecular Pathology", PancraGEN® combines the insights that come from first line testing such as serum markers (Amylase, CEA), imaging, and cytology with those derived from measuring DNA quantity, quality, and tumor suppressor genes (LOH) that are highly correlated to pancreatic cancer.PancraGENLearn More
RespriDX™ is a molecular test that helps physicians differentiate between metastatic or a newly formed primary lung cancer. RespriDX™ also utilizes our PathFinderTG® platform to compare the genomic fingerprint of two or more sites where lung cancer tumors are present.RespriDXLearn More
BarreGen® is an esophageal cancer risk classifier for Barrett's Esophagus that predicts which patients with Barrett's Esophagus will progress to Esophageal cancer over time. BarreGen® also utilizes our PathFinderTG® platform.